Skip to main content
. 2019 Apr 1;26(2):e175–e179. doi: 10.3747/co.26.4595

TABLE III.

Best response at second-line therapy with cabozantinib in 40 patients and nivolumab in 140 patients

Response Cabozantinib [n (%)] Nivolumab [n (%)]
Complete response 1 (3) 2 (1)
Partial response 7 (18) 28 (20)
Stable disease 23 (58) 48 (34)
Progressive disease 9 (23) 62 (44)
Overall response rate 8 (20) 30 (21)
p=0.85